Scientists Come Closer to Reversing Aging by Generating
Young Mesenchymal Stem Cells from Blood of a 75-Year-Old
Donor
MIAMI
BEACH, Fla., May 23, 2024
/PRNewswire/ -- Immorta Bio Inc, a science-based Life
Extension company has announced patent filing on successful
treatment of the carbon tetrachloride model of liver failure using
its PMSC-11 stem cell therapy. Data disclosed in its filed patent
demonstrates PMSC-11 potently suppresses liver damage as detected
by preserving albumin production and blocking catastrophic rises in
liver enzymes which are typical in liver failure.
Importantly, the administration of the PMSC-11 stem cell product
induced a potent increase in a totally unexpected cytokine whose
expression in some publications has been correlated with
accelerated recovery from hepatic failure.
"The PMSC-11 product is a personalized mesenchymal stem cell
that is generated to possess a significantly younger biological age
than the patient," said Dr. Thomas
Ichim, President and Chief Scientific Officer of Immorta
Bio. "The PMSC-11 cells, utilized in the experiments reported
today, demonstrated safety as well as therapeutic efficacy,
supporting continued development of this "First in Class" Stem Cell
Therapy for liver failure."
"Liver Failure is the fifth leading cause of death world-wide
with no therapeutic options besides transplantation. We are
conducting pre-clinical experiments in animals using human cells to
demonstrate safety and efficacy of these cells before applying to
the FDA to begin clinical trials," said Dr. Vlad Bykoriz,
Chief Medical Officer of Immorta Bio.
Stem cells have previously been demonstrated to possess some
therapeutic effects on liver failure, however allogeneic stem
cells, that have been mostly used so far, are eventually rejected
by the patient. And autologous adult stem cells are limited in
numbers, and often dysfunctional because of preexisting conditions.
The PMSC product overcomes some of the shortcomings of existing
stem cell therapeutics. These cells are patient specific,
"biologically younger", and can be created in unlimited numbers
because they are derived from the embryonic-like PRC.
"Our vision of significant life extension is based on
revivifying aged or damaged organs," said Dr. Boris Reznik,
CEO and Chairman of the Company. "We generate "Amenable Stem
Cells" (ASC) from a tablespoon of patient's blood and utilize
our proprietary technology to transform these ASC into
"Personalized Regenerative Cells" (PRC). The PRC are
very similar to the immortal embryonic stem cells and are generated
by "reverse differentiation" of the ASC from the patient's
blood. These PRC should allow for creation and introduction
of cells for any tissue or organ whose regeneration is desired.
Today's announcement provides a glimpse into the potential power of
our Stem Cell Revivify™ path to organ and eventually whole-body
rejuvenation."
About Immorta Bio:
Immorta Bio is a biotechnology company developing efficient
and practical personalized stem cell platforms aimed at Treating
Diseases of Aging and Treating Aging as Disease™. Our objective is
to rejuvenate the old and damaged organs to the healthy state,
achieving, what we call, Stem Cell Revivify™. By solving the
problem of diseases of aging, we can potentially dramatically
increase our patients' longevity.
For more information, please visit the Immorta Bio website
at https://www.immortabio.com or find them on X at
https://twitter.com/ImmortaBio.
Media Contacts:
Dr. Boris
Reznik
Immorta Bio
https://www.immortabio.com
+1 305-632-2939
@immortabio
View original content to download
multimedia:https://www.prnewswire.com/news-releases/immorta-bio-inc-a-longevity-company-announces-a-significant-breakthrough-in-treatment-of-liver-failure-302154227.html
SOURCE Immorta Bio, Inc.